Cortexyme’s ongoing Phase 2/3 GAIN clinical trial, which is evaluating the investigational treatment COR388 (atuzaginstat) in people with mild to moderate Alzheimer’s disease, has been approved to continue as planned to its one-year endpoint, the company said. Topline results from the study, testing whether COR388 can lessen dementia and neurodegeneration in Alzheimer’s, are expected on time in December 2021. The trial recommendation was given by the independent Data Monitoring Committee (DMC) — a panel of independent…
You must be logged in to read/download the full post.
The post Cortexyme’s COR388 GAIN Trial Advances to Endpoint; Results Expected Late 2021 appeared first on BioNewsFeeds.